SJ1008030 formic

Cat. No.: HY-147330B

Molecular Formula: $C_{43}H_{45}N_{13}O_9S$

Molecular Weight: 919.96

Target: PROTACs; JAK

Pathway: PROTAC; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (135.88 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.0870 mL	5.4350 mL	10.8700 mL
	5 mM	0.2174 mL	1.0870 mL	2.1740 mL
	10 mM	0.1087 mL	0.5435 mL	1.0870 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SJ1008030 (compound 8) formic is a JAK2 PROTAC which selectively degrades JAK2. SJ1008030 formic inhibits MHH–CALL-4 cell growth with an IC_{50} of 5.4 nM. SJ1008030 formic can be used for the research of leukemia[1].

IC_{50} & Target

JAK2

In Vitro

SJ1008030 (compound 8) formic (72 h) shows activity in CRLF2r cell lines (MHH–CALL-4), with an IC_{50} of 5.4 nM[1].
SJ1008030 (0-4.3 μM; 72 h) formic degrades JAKs, GSPT1, and IKZF1 in a dose-dependent manner in MHH–CALL-4 cells[1].
SJ1008030 (0-10 μM; 24h) formic dose-dependently degrades JAK2 and GSPT1 protein in xenograft bone marrow SJBALL021415 cells, indicating the inhibition of JAK-STAT signaling pathway[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Chang Y, et al. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia. Blood. 2021 Dec 9;138(23):2313-2326.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA